Page 18 - Read Online

Dong et al. UPI peptide as cancer therapeutic

Xia L, Cremona O, De Camilli P, Min W, Chen H. Endothelial epsin 30. Bogdanowich-Knipp SJ, Jois DS, Siahaan TJ. The effect of
deficiency decreases tumor growth by enhancing VEGF signaling. J conformation on the solution stability of linear vs. cyclic RGD
Clin Invest 2012;122:4424-38. peptides. J Pept Res 1999;53:523-9.
21. Chang B, Tessneer KL, McManus J, Liu X, Hahn S, Pasula S, Wu 31. Liu S. Radiolabeled cyclic RGD peptides as integrin alpha(v)beta(3)-
H, Song H, Chen Y, Cai X, Dong Y, Brophy ML, Rahman R, Ma targeted radiotracers: maximizing binding affinity via bivalency.
JX, Xia L, Chen H. Epsin is required for Dishevelled stability and Bioconjug Chem 2009; 20:2199-213.
Wnt signalling activation in colon cancer development. Nat Commun 32. Roxin Á, Zheng G. Flexible or fixed: a comparative review of linear
2015;6:6380. and cyclic cancer-targeting peptides. Future Med Chem 2012;4:1601-
22. Tessneer KL, Pasula S, Cai X, Dong Y, McManus J, Liu X, Yu L, 18.
Hahn S, Chang B, Chen Y, Griffin C, Xia L, Adams RH, Chen H. 33. Hofmann K, Falquet L. A ubiquitin-interacting motif conserved in
Genetic reduction of vascular endothelial growth factor receptor 2 components of the proteasomal and lysosomal protein degradation
rescues aberrant angiogenesis caused by epsin deficiency. Arterioscler systems. Trends Biochem Sci 2001;26:347-50.
Thromb Vasc Biol 2014;34:331-7. 34. Dahlman JE, Barnes C, Khan OF, Thiriot A, Jhunjunwala S, Shaw
23. Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, TE, Xing Y, Sager HB, Sahay G, Speciner L, Bader A, Bogorad RL,
Girard OM, Hanahan D, Mattrey RF, Ruoslahti E. Tissue-penetrating Yin H, Racie T, Dong Y, Jiang S, Seedorf D, Dave A, Singh Sandhu
delivery of compounds and nanoparticles into tumors. Cancer Cell K, Webber MJ, Novobrantseva T, Ruda VM, Lytton-Jean AK, Levins
2009;16:510-20. CG, Kalish B, Mudge DK, Perez M, Abezgauz L, Dutta P, Smith L,
24. Sugahara KN, Teesalu T, Karmali PP, Kotamraju VR, Agemy L, Charisse K, Kieran MW, Fitzgerald K, Nahrendorf M, Danino D,
Greenwald DR, Ruoslahti E. Coadministration of a tumor-penetrating Tuder RM, von Andrian UH, Akinc A, Panigrahy D, Schroeder A,
peptide enhances the efficacy of cancer drugs. Science 2010;328:1031- Koteliansky V, Langer R, Anderson DG. In vivo endothelial siRNA
5. delivery using polymeric nanoparticles with low molecular weight.
25. Weis SM, Cheresh DA. αV integrins in angiogenesis and cancer. Cold Nat Nanotechnol 2014;9:648-55.
Spring Harb Perspect Med 2011;1:a006478. 35. Guo P, Yang J, Jia D, Moses MA, Auguste DT. ICAM-1-targeted,
26. Kovárová M, Tolar P, Arudchandran R, Dráberová L, Rivera J, Dráber Lcn2 siRNA-encapsulating liposomes are potent anti-angiogenic
P. Structure-function analysis of Lyn kinase association with lipid agents for triple negative breast cancer. Theranostics 2016;6:1-13.
rafts and initiation of early signaling events after Fcepsilon receptor I 36. Guo P, You JO, Yang J, Jia D, Moses MA, Auguste DT. Inhibiting
aggregation. Mol Cell Biol 2001;21:8318-28. metastatic breast cancer cell migration via the synergy of targeted,
27. Chen H, De Camilli P. The association of epsin with ubiquitinated pH-triggered siRNA delivery and chemokine axis blockade. Mol
cargo along the endocytic pathway is negatively regulated by its Pharm 2014;11:755-65.
interaction with clathrin. Proc Natl Acad Sci U S A 2005;102:2766-71. 37. Cong L, Zhang F. Genome engineering using CRISPR-Cas9 system.
28. Kurosaki T. Regulation of B-cell signal transduction by adaptor Methods Mol Biol 2015;1239:197-217.
proteins. Nat Rev Immunol 2002;2:354-63. 38. Heckl D, Charpentier E. Toward whole-transcriptome editing with
29. Solution structure of Vps27 UIM-ubiquitin complex important CRISPR-Cas9. Mol Cell 2015;58:560-2.
for endosomal sorting and receptor downregulation. EMBO J 39. Sternberg SH, Doudna JA. Expanding the biologist’s toolkit with
2003;22:4597-606. CRISPR-Cas9. Mol Cell 2015;58:568-74.

Vessel Plus ¦ Volume 1 ¦ March 31, 2017 11